Doctor speaking with patient. Image credit: Canva
Monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body’s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs, atezolizumab, is approved to treat certain cancers. Researchers want to find out if lower doses of this drug might provide the same benefit with fewer adverse effects.
A clinical trial led by James L. Gulley., M.D., Ph.D., Co-Director and Senior Investigator in the Center for Immuno-Oncology, is researching atezolizumab for adults with locally advanced or metastatic cancers.
The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for medical care received at the Clinical Center.
For more information, please contact the NCI Cancer Information Service at 1-888-624-1937 or nciinfo@mail.nih.gov
Clinicaltrials.gov identifier: NCT06066138
NCI Protocol ID: IRB001559
Official Title: A Feasibility Multicenter Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.
